Anne Pavy-Le Traon1,2, Nikki Cotterill3, Gerard Amarenco4, Susanne Duerr5, Horacio Kaufmann6, Heinz Lahrmann7, François Tison8, Gregor K Wenning5, Christopher G Goetz9, Werner Poewe5, Cristina Sampaio10, Anette Schrag11, Olivier Rascol1,12, Pablo Martinez-Martin13, Glenn T Stebbins9. 1. French Reference Center for MSA, Department of Neurology University Hospital of Toulouse France. 2. Institute of Cardiovascular and Metabolic Diseases (I2MC-UMR1048) Toulouse France. 3. Bristol Urological Institute, Southmead Hospital Westbury-on-Trym Bristol United Kingdom. 4. Neuro-Urology Department Hôpital Tenon, and GRC01 UPMC Paris France. 5. Department of Neurology University Hospital Innsbruck Austria. 6. Department of Neurology New York University New York USA. 7. Private Praxis Vienna Austria. 8. Institute for Neurodegenerative Diseases, University of Bordeaux University Hospital of Bordeaux Bordeaux France. 9. Department of Neurological Services Rush University School of Medicine Chicago IL USA. 10. Laboratory of Clinical Pharmacology and Therapeutics Lisbon School of Medicine Lisbon Portugal. 11. Department of Clinical Neurosciences, Royal Free Hospital University College London London United Kingdom. 12. Laboratoire de Pharmacologie Médicale et Clinique Toulouse France. 13. National Center of Epidemiology and CIBERNED Carlos III Institute of Health Madrid Spain.
Abstract
BACKGROUND: The prevalence of lower urinary tract symptoms (LUTS) is high in Parkinson's disease (PD). These problems negatively affect quality of life and include both storage and voiding problems. The International Parkinson and Movement Disorder Society established a task force to review clinical rating scales/questionnaires for the assessment of urinary symptoms in PD. METHODS: According to prespecified criteria, these scales/questionnaires were classified as "Recommended" or "Recommended with caveats" when clinimetric properties were satisfactory for Recommended status but had not been assessed specifically in PD, "Suggested" or "Listed." These assessments were applied to rate scales as screening tools for the diagnosis of LUTS and for the rating of symptom severity. RESULTS: Among scales that included LUTS but focused on overall autonomic or non-motor symptoms in PD, no scale reached the clinimetric rigor to be designated as Recommended or Recommended with caveats, but some were Suggested for either diagnostic screening tools or severity measures. Among primary urological scales, most are well validated in urological setting, but none was validated specifically in PD. DAN-PSS (Danish PSS), ICIQ (International Consultation for Incontinence Questionnaire)-MLUTS (Male Lower Urinary Tract Symptoms), OABq, OABq-SF (ICIQ-OABqol), OAB-V8 (as screening tool), and OABSS (OAB Symptom Score) met criteria for Recommended with caveats. CONCLUSION: The Task Force does not recommend the development of a new scale. However, all above-mentioned questionnaires need to be studied further and specifically validated in PD.
BACKGROUND: The prevalence of lower urinary tract symptoms (LUTS) is high in Parkinson's disease (PD). These problems negatively affect quality of life and include both storage and voiding problems. The International Parkinson and Movement Disorder Society established a task force to review clinical rating scales/questionnaires for the assessment of urinary symptoms in PD. METHODS: According to prespecified criteria, these scales/questionnaires were classified as "Recommended" or "Recommended with caveats" when clinimetric properties were satisfactory for Recommended status but had not been assessed specifically in PD, "Suggested" or "Listed." These assessments were applied to rate scales as screening tools for the diagnosis of LUTS and for the rating of symptom severity. RESULTS: Among scales that included LUTS but focused on overall autonomic or non-motor symptoms in PD, no scale reached the clinimetric rigor to be designated as Recommended or Recommended with caveats, but some were Suggested for either diagnostic screening tools or severity measures. Among primary urological scales, most are well validated in urological setting, but none was validated specifically in PD. DAN-PSS (Danish PSS), ICIQ (International Consultation for Incontinence Questionnaire)-MLUTS (Male Lower Urinary Tract Symptoms), OABq, OABq-SF (ICIQ-OABqol), OAB-V8 (as screening tool), and OABSS (OAB Symptom Score) met criteria for Recommended with caveats. CONCLUSION: The Task Force does not recommend the development of a new scale. However, all above-mentioned questionnaires need to be studied further and specifically validated in PD.
Authors: D M Castro-Díaz; M Esteban-Fuertes; J Salinas-Casado; S Bustamante-Alarma; J L Gago-Ramos; A Galacho-Bech; M J García-Matres; L A Rodríguez-Toves; C Zubiaur-Líbano; A Collado-Serra; J E Batista-Miranda; A Ortiz-Gámiz Journal: Actas Urol Esp Date: 2013-10-10 Impact factor: 0.994
Authors: Louis S Matza; Christine L Thompson; Joel Krasnow; Jessica Brewster-Jordan; Teresa Zyczynski; Karin S Coyne Journal: Neurourol Urodyn Date: 2005 Impact factor: 2.696
Authors: Nelson Hwynn; Ihtsham U Haq; Irene A Malaty; Andrew S Resnick; Michael S Okun; Danica S Carew; Genko Oyama; Yunfeng Dai; Samuel S Wu; Ramon L Rodriguez; Charles E Jacobson; Hubert H Fernandez Journal: Parkinsons Dis Date: 2011-07-26
Authors: Ana Gómez-López; Arantxa Sánchez-Sánchez; Elena Natera-Villalba; Victoria Ros-Castelló; Álvaro Beltrán-Corbellini; Samira Fanjul-Arbós; Isabel Pareés Moreno; José Luis López-Sendon Moreno; Juan Carlos Martínez Castrillo; Araceli Alonso-Canovas Journal: Brain Sci Date: 2021-01-06
Authors: Emma Tenison; Fiona E Lithander; Matthew D Smith; Danielle Pendry-Brazier; Yoav Ben-Shlomo; Emily J Henderson Journal: BMJ Open Date: 2022-05-11 Impact factor: 3.006